KR102096604B1 - 신규한 crispr 연관 단백질 및 이의 용도 - Google Patents
신규한 crispr 연관 단백질 및 이의 용도 Download PDFInfo
- Publication number
- KR102096604B1 KR102096604B1 KR1020190169918A KR20190169918A KR102096604B1 KR 102096604 B1 KR102096604 B1 KR 102096604B1 KR 1020190169918 A KR1020190169918 A KR 1020190169918A KR 20190169918 A KR20190169918 A KR 20190169918A KR 102096604 B1 KR102096604 B1 KR 102096604B1
- Authority
- KR
- South Korea
- Prior art keywords
- lys
- ile
- leu
- glu
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
도 2a는 발굴된 Cas12a의 계통수를 나타낸 것이다.
도 2b는 신규 Cas12a와 AsCas12a의 구조도를 나타낸 것이다.
도 3 내지 도 8은 ESPript 프로그램을 이용하여 정렬한 기존의 Cas12a 및 본 발명의 mgCas12a의 아미노산 서열을 나타낸 것이다.
도 9a 및 9b는 Cas12a 및 본 발명의 mgCas12a의 서열 정보를 비교 및 정리하여 표로 나타낸 것이다.
도 10 내지 도 12는 pH에 따른 본 발명에 따른 mgCas12a의 활성을 확인한 것이다. 한편, 도 10의 crRNA #1은 서열번호 25의 염기서열을 가지고, 도 11의 crRNA #2는 서열번호 26의 염기서열을 가진다.
도 13은 표적 핵산 서열 및 crRNA가 결합하는 위치를 표시하여 나타낸 것이다.
도 14는 CCR5 및 DNMT1 각 유전자의 crRNA를 이용한 유전자 편집 효율을 단백질별(mock, mgCas12a-1 및 mgCas12a-2)로 나타낸 것이다.
도 15는 FucT14-1 및 FucT14-2 각 유전자의 두 가지 crRNA를 이용한 유전자 편집 효율을 단백질별(FnCpf1, mgCas12a-1 및 mgCas12a-2)로 확인하여 나타낸 것이다.
도 16a 및 도 16b는 FnCas12a, WT mgCas12a-1 또는 WT mgCas12a-2 단백질의 DNA 절단 활성을 확인한 것이다.
도 17은 기존 Cas12a(AsCas12a, FnCas12a 또는 LbCas12a)와 신규 Cas12a(WT mgCas12a-1, d_mgCas12a-1, WTmgCas12a-2 또는 d_mgCas12a-2)의 비특이적인 DNase 기능을 확인한 것이다.
도 18a 및 도 18b는 crRNA 없이 FnCas12a, WT mgCas12a-1 또는 WT mgCas12a-2 단백질이 비특이적인 DNase 기능을 가지는지를 확인한 것이다.
도 19는 mgCas12a가 기존 Cas12a의 5' handle을 이용하여 DNA 절단이 가능한지를 확인한 것이다.
도 20a 및 도 20b는 이가이온들에서 FnCas12a, mgCas12a-1 또는 mgCas12a-2 단백질의 DNA 절단 활성을 나타낸 것이다.
| Genes | crRNA sequence (5'-3') |
| CCR5 | CACCGAAUUUCUACUGUUGUAGAUGGAGUGAAGGGAGAGUUUGUCAAUUUUUUG (서열번호 12) |
| DNMT1 | GGUCAAUUUCUACUGUUGUAGAUGCUCAGCAGGCACCUGCCUCUUUU (서열번호 13) |
| Genes | Adapter primer sequence (5'-3') |
| CCR5 | TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGTATTTCTGTTCAGATCAC (서열번호 15) |
| GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCCCATCAATTATAGAAAGCC (서열번호 16) | |
| DNMT1 | TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTGCACACAGCAGGCCTTTG (서열번호 17) |
| GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCCAATAAGTGGCAGAGTGC (서열번호 18) |
| Enzyme 용액 | 20 mL |
| 1.0% Cellulase R10 | 200 mg |
| 0.5% Macerozyme R10 | 100 mg |
| 0.4 M Mannitol | 10 mL (0.8 M Mannitol Stock solution) |
| 20 mM MES, pH 5.7 | 4 mL (100 mM MES Stock solution, pH 5.7) |
| 20 mM KCl | 200 μL (2 M KCl Stock solution) |
| 위 시약들 조합한 후 60도에서 10분간 배양한 후 아래 시약을 조합한다. | |
| 10 mM CaCl2·2H2O | 200 μL (1 M CaCl2·2H2O Stock solution) |
| 0.1 % BSA | 200 μL (10% BSA Stock solution) |
| MMG 용액 | 10 mL |
| 0.4 M Mannitol | 5 mL (0.8 M Mannitol Stock solution) |
| 4 mM MES, pH 5.7 | 400 μL (0.1 M MES Stock solution, pH5.7) |
| 15 mM MgCl2 | 150 μL (1 M MgCl2 Stock solution) |
| Nuclease-free water | 4.45 mL |
| PEG 용액 | 5 mL |
| 0.2 M Mannitol | 1.25 mL (0.8 M Mannitol Stock solution) |
| 40%W/V PEG-4000 | 2 g (Polyethylene glycol 4000) |
| 100 mM CaCl2·2H2O | 500 μL (1 M CaCl2·2H2O Stock solution) |
| Nuclease-free water | 1.5 mL |
| W5 용액 | 50 mL |
| 154 mM NaCl | 3.85 mL (2 M NaCl Stock solution) |
| 125 mM CaCl2·2H2O | 6.25 mL (1 M CaCl2·2H2O Stock solution) |
| 5 mM KCI | 125 μL (2 M KCl Stock solution) |
| 2 mM MES, pH 5.7 | 500 μL (0.1 M MES Stock solution) |
| Nuclease-free water | 39.275 mL |
| Target gene |
crRNA | Nuclease | Total Sequences |
With both indicator sequences |
More than minimum frequency |
Insertions | Deletions | Indel frequency |
| FucT14-1 | 2 | none | 161551 | 161421 | 160896 | 4 | 180 | 184 (0.1%) |
| mgCas12a-1 | 124361 | 124255 | 123844 | 3 | 168 | 171 (0.1%) | ||
| mgCas12a-2 | 99154 | 99053 | 98734 | 0 | 131 | 131 (0.1%) | ||
| FnCpf1 | 50060 | 50022 | 49808 | 0 | 63 | 63 (0.1%) | ||
| 4 | none | 161551 | 161411 | 160899 | 4 | 178 | 182 (0.1%) | |
| mgCas12a-1 | 106782 | 106706 | 106330 | 0 | 1877 | 1877 (1.8%) | ||
| mgCas12a-2 | 126665 | 126544 | 126057 | 79 | 885 | 964 (0.8%) | ||
| FnCpf1 | 64554 | 64501 | 64272 | 15 | 470 | 485 (0.8%) | ||
| FucT14-2 | 2 | none | 49459 | 49422 | 49192 | 2 | 49 | 51 (0.1%) |
| mgCas12a-1 | 81191 | 81101 | 80738 | 0 | 90 | 90 (0.1%) | ||
| mgCas12a-2 | 83694 | 83614 | 83286 | 0 | 99 | 99 (0.1%) | ||
| FnCpf1 | 108803 | 108682 | 108260 | 0 | 112 | 112 (0.1%) | ||
| 4 | none | 49459 | 49427 | 49199 | 2 | 49 | 51 (0.1%) | |
| mgCas12a-1 | 54918 | 54854 | 54532 | 6 | 689 | 695 (1.3%) | ||
| mgCas12a-2 | 127825 | 127691 | 127213 | 2 | 143 | 145 (0.1%) | ||
| FnCpf1 | 64265 | 64168 | 63882 | 0 | 162 | 162 (0.3%) |
| Target Gene | crRNA (primer name) |
crRNA sequence(PAM site) |
|
NbFucT14_1
NbFucT14_2 |
NbFTa14_1/2-2 | TTTGGATAATTTGTACTCTTGTCGATGT (서열번호 19) |
| NbFTa14_1/2-4 | TTTAGTCCACAAACAGCTAAGCCCACAT (서열번호 20) |
| Target gene | Primer name | Sequence | Size (bp) |
| NbFucT14_1 | NGS NbFTa14_1_F | TGAGCTGAAGATGGATTATG (서열번호 21) |
216 |
| NGS NbFTa14_1_R | TCATGCTTAAGATAAAAGAG (서열번호 22) |
||
| NbFucT14_2 | NGS NbFTa14_2_F | TCATGAGCTTAAGATGGATC (서열번호 23) |
217 |
| NGS NbFTa14_2_R | GTTTAAGCTAAAAGAACTAC (서열번호 24) |
Claims (11)
- 서열번호 3의 아미노산 서열로 이루어진 Cas12a 단백질.
- 제1항에 있어서,
상기 서열번호 3의 아미노산 서열로 이루어진 Cas12a 단백질은 서열번호 4의 염기서열에 의해 코딩되는 것인, Cas12a 단백질. - 제1항에 있어서,
상기 단백질이 엔도뉴클레아제 활성을 갖는 것을 특징으로 하는, Cas12a 단백질. - 제1항에 있어서,
상기 서열번호 3의 아미노산 서열로 이루어진 Cas12a 단백질은 pH 7.0 내지 pH 7.9에서 최적의 활성을 갖는 것을 특징으로 하는, Cas12a 단백질. - 서열번호 3의 아미노산 서열 중 930번째 위치의 라이신(Lys)이 다른 아미노산으로 치환된 Cas12a 단백질.
- 제5항에 있어서,
상기 다른 아미노산은 아르기닌(Arg), 히스티딘(His), 아스파르트산(Asp), 글루탐산(Glu), 세린(Ser), 트레오닌(Thr), 아스파라긴(Asn), 글루타민(Gln), 티로신(Tyr), 알라닌(Ala), 이소류신(Ile), 류신(Leu), 발린(Val), 페닐알라닌(Phe), 메티오닌(Met), 트립토판(Trp), 글리신(Gly), 프롤린(Pro), 및 시스테인(Cys)으로 구성된 군에서 선택되는 어느 하나인, Cas12a 단백질. - 서열번호 3의 아미노산 서열 중 873번째 위치의 아스파르트산(Asp)이 다른 아미노산으로 치환된 Cas12a 단백질.
- 제7항에 있어서,
상기 다른 아미노산은 아르기닌(Arg), 히스티딘(His), 글루탐산(Glu), 세린(Ser), 트레오닌(Thr), 아스파라긴(Asn), 글루타민(Gln), 티로신(Tyr), 알라닌(Ala), 라이신(Lys), 이소류신(Ile), 류신(Leu), 발린(Val), 페닐알라닌(Phe), 메티오닌(Met), 트립토판(Trp), 글리신(Gly), 프롤린(Pro), 및 시스테인(Cys)으로 구성된 군에서 선택되는 어느 하나인, Cas12a 단백질. - 제7항에 있어서,
상기 단백질이 엔도뉴클레아제 활성이 감소된 것인, Cas12a 단백질. - 제1항 또는 제5항에 기재된 Cas12a 단백질; 및 암세포에 특이적으로 존재하는 핵산 서열을 타겟팅하는 crRNA를 유효성분으로 포함하는 암 치료용 약학적 조성물.
- 제10항에 있어서,
상기 Cas12a 단백질은 서열번호 3 또는 서열번호 6의 아미노산 서열로 이루어진 것인, 약학적 조성물.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180093336 | 2018-08-09 | ||
| KR1020180093336 | 2018-08-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190097531A Division KR102096592B1 (ko) | 2018-08-09 | 2019-08-09 | 신규한 crispr 연관 단백질 및 이의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200018364A KR20200018364A (ko) | 2020-02-19 |
| KR102096604B1 true KR102096604B1 (ko) | 2020-04-02 |
Family
ID=69415629
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190097531A Active KR102096592B1 (ko) | 2018-08-09 | 2019-08-09 | 신규한 crispr 연관 단백질 및 이의 용도 |
| KR1020190169918A Active KR102096604B1 (ko) | 2018-08-09 | 2019-12-18 | 신규한 crispr 연관 단백질 및 이의 용도 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190097531A Active KR102096592B1 (ko) | 2018-08-09 | 2019-08-09 | 신규한 crispr 연관 단백질 및 이의 용도 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210292722A1 (ko) |
| EP (1) | EP3835418A4 (ko) |
| JP (2) | JP2021532819A (ko) |
| KR (2) | KR102096592B1 (ko) |
| CN (1) | CN112567031B (ko) |
| AU (1) | AU2019319377A1 (ko) |
| BR (1) | BR112021002476A2 (ko) |
| CA (1) | CA3109105A1 (ko) |
| EA (1) | EA202190454A1 (ko) |
| IL (1) | IL280631A (ko) |
| MX (1) | MX2021001578A (ko) |
| PH (1) | PH12021550256A1 (ko) |
| SG (1) | SG11202101227TA (ko) |
| WO (1) | WO2020032711A1 (ko) |
| ZA (1) | ZA202101250B (ko) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220039188A (ko) * | 2020-09-22 | 2022-03-29 | (주)지플러스생명과학 | 신규한 crispr 연관 단백질 및 이의 용도 |
| WO2022065867A1 (ko) * | 2020-09-22 | 2022-03-31 | (주)지플러스생명과학 | 변형된 cas12a 단백질 및 이의 용도 |
| WO2024167317A1 (ko) * | 2023-02-10 | 2024-08-15 | 주식회사 엔세이지 | 신규 CRISPR/Cas12a 조성물 및 이의 표적 핵산 검출 용도 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057961A1 (en) | 2014-10-10 | 2016-04-14 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| WO2020006423A1 (en) | 2018-06-29 | 2020-01-02 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| CN113227367B (zh) | 2018-08-09 | 2023-05-12 | G+Flas生命科学公司 | 用cas12a蛋白进行基因组工程的组合物和方法 |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| WO2025091199A1 (zh) * | 2023-10-31 | 2025-05-08 | 深圳华大生命科学研究院 | 新型Cas12a核酸酶BEST5及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160208243A1 (en) | 2015-06-18 | 2016-07-21 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| WO2017127807A1 (en) * | 2016-01-22 | 2017-07-27 | The Broad Institute Inc. | Crystal structure of crispr cpf1 |
| US20170233756A1 (en) | 2016-02-15 | 2017-08-17 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| WO2018013990A1 (en) | 2016-07-15 | 2018-01-18 | Zymergen Inc. | Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106550603A (zh) * | 2014-07-28 | 2017-03-29 | 陶氏环球技术有限责任公司 | 用于lcd的滤色片的酞菁化合物 |
| AU2016299271B2 (en) * | 2015-07-25 | 2022-09-22 | Habib FROST | A system, device and a method for providing a therapy or a cure for cancer and other pathological states |
| EP3374494A4 (en) * | 2015-11-11 | 2019-05-01 | Coda Biotherapeutics, Inc. | CRISPR COMPOSITIONS AND METHODS OF USE FOR GENE THERAPY |
| WO2017096328A1 (en) * | 2015-12-04 | 2017-06-08 | Caribou Biosciences, Inc. | Engineered nucleic-acid targeting nucleic acids |
| WO2017099494A1 (ko) * | 2015-12-08 | 2017-06-15 | 기초과학연구원 | Cpf1을 포함하는 유전체 교정용 조성물 및 그 용도 |
| CA3026112A1 (en) * | 2016-04-19 | 2017-10-26 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
| KR102858467B1 (ko) * | 2016-08-12 | 2025-09-11 | 주식회사 툴젠 | 면역세포의 면역조절 유전자의 활성 조절을 위한 조성물 및 그 용도 |
| EP3526326A4 (en) * | 2016-10-12 | 2020-07-29 | The Regents of The University of Colorado, A Body Corporate | NEW MODIFIED AND CHEMERICAL NUCLEASES |
-
2019
- 2019-08-09 MX MX2021001578A patent/MX2021001578A/es unknown
- 2019-08-09 KR KR1020190097531A patent/KR102096592B1/ko active Active
- 2019-08-09 JP JP2021506585A patent/JP2021532819A/ja not_active Ceased
- 2019-08-09 BR BR112021002476-0A patent/BR112021002476A2/pt not_active Application Discontinuation
- 2019-08-09 CN CN201980053705.0A patent/CN112567031B/zh active Active
- 2019-08-09 WO PCT/KR2019/010110 patent/WO2020032711A1/ko not_active Ceased
- 2019-08-09 SG SG11202101227TA patent/SG11202101227TA/en unknown
- 2019-08-09 AU AU2019319377A patent/AU2019319377A1/en not_active Abandoned
- 2019-08-09 EA EA202190454A patent/EA202190454A1/ru unknown
- 2019-08-09 CA CA3109105A patent/CA3109105A1/en active Pending
- 2019-08-09 US US17/266,882 patent/US20210292722A1/en not_active Abandoned
- 2019-08-09 EP EP19846625.2A patent/EP3835418A4/en not_active Withdrawn
- 2019-12-18 KR KR1020190169918A patent/KR102096604B1/ko active Active
-
2021
- 2021-02-03 PH PH12021550256A patent/PH12021550256A1/en unknown
- 2021-02-03 IL IL280631A patent/IL280631A/en unknown
- 2021-02-24 ZA ZA2021/01250A patent/ZA202101250B/en unknown
-
2024
- 2024-04-12 JP JP2024064761A patent/JP7727042B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160208243A1 (en) | 2015-06-18 | 2016-07-21 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| WO2017127807A1 (en) * | 2016-01-22 | 2017-07-27 | The Broad Institute Inc. | Crystal structure of crispr cpf1 |
| US20170233756A1 (en) | 2016-02-15 | 2017-08-17 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| WO2017141173A2 (en) * | 2016-02-15 | 2017-08-24 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| WO2018013990A1 (en) | 2016-07-15 | 2018-01-18 | Zymergen Inc. | Scarless dna assembly and genome editing using crispr/cpf1 and dna ligase |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220039188A (ko) * | 2020-09-22 | 2022-03-29 | (주)지플러스생명과학 | 신규한 crispr 연관 단백질 및 이의 용도 |
| WO2022065867A1 (ko) * | 2020-09-22 | 2022-03-31 | (주)지플러스생명과학 | 변형된 cas12a 단백질 및 이의 용도 |
| KR102497690B1 (ko) * | 2020-09-22 | 2023-02-10 | (주)지플러스생명과학 | 신규한 crispr 연관 단백질 및 이의 용도 |
| WO2024167317A1 (ko) * | 2023-02-10 | 2024-08-15 | 주식회사 엔세이지 | 신규 CRISPR/Cas12a 조성물 및 이의 표적 핵산 검출 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3835418A1 (en) | 2021-06-16 |
| US20210292722A1 (en) | 2021-09-23 |
| PH12021550256A1 (en) | 2021-11-03 |
| MX2021001578A (es) | 2021-06-15 |
| IL280631A (en) | 2021-03-25 |
| SG11202101227TA (en) | 2021-03-30 |
| KR20200018364A (ko) | 2020-02-19 |
| ZA202101250B (en) | 2022-09-28 |
| WO2020032711A1 (ko) | 2020-02-13 |
| JP2024099604A (ja) | 2024-07-25 |
| CN112567031B (zh) | 2024-08-06 |
| EA202190454A1 (ru) | 2021-04-22 |
| CN112567031A (zh) | 2021-03-26 |
| AU2019319377A1 (en) | 2021-03-11 |
| CA3109105A1 (en) | 2020-02-13 |
| KR20200018345A (ko) | 2020-02-19 |
| EP3835418A4 (en) | 2022-05-04 |
| BR112021002476A2 (pt) | 2021-07-27 |
| KR102096592B1 (ko) | 2020-04-02 |
| JP7727042B2 (ja) | 2025-08-20 |
| JP2021532819A (ja) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102096604B1 (ko) | 신규한 crispr 연관 단백질 및 이의 용도 | |
| AU2012267271B2 (en) | dsRNA endoribonucleases | |
| DK2140006T3 (en) | DELTA-5 desaturases AND USE THEREOF FOR THE PRODUCTION OF polyunsaturated fatty acids | |
| CN113302303B (zh) | 经修饰的丝状真菌宿主细胞 | |
| CN105176936B (zh) | 复制耐受型的西门利克森林病毒的亚克隆及制备方法和应用 | |
| CN110540989A (zh) | 基于pcr技术克隆已知区域旁邻的未知dna序列的引物及方法 | |
| CN111171132B (zh) | 乌鳢抗菌肽 | |
| CN101693901B (zh) | 一种大肠杆菌-棒状杆菌穿梭型诱导表达载体pDXW-8及其构建方法 | |
| CN101302531A (zh) | 一种在大肠杆菌-链霉菌-假单胞菌之间穿梭表达的bac载体及其构建方法 | |
| CN110734480B (zh) | 大肠杆菌分子伴侣GroEL/ES在协助合成植物Rubisco中的应用 | |
| KR20230110271A (ko) | 식물성 칸나비노이드들의 생산에 사용하기 위한 개선된 활성을 갖는 올리베톨산 시클라아제 변이체들 | |
| CN113061626B (zh) | 一种组织特异性敲除斑马鱼基因的方法及应用 | |
| CN113710268B (zh) | 药物递送组合物 | |
| KR101566371B1 (ko) | 구제역 아시아1 혈청형의 표준백신 바이러스의 방어항원을 발현하는 재조합 구제역 바이러스 및 이의 제조 방법 | |
| CN114317605B (zh) | 一种小胶质细胞钾离子探针转基因小鼠模型的构建方法 | |
| CN114874332B (zh) | 经修饰的rnf112作为治疗als药物的应用 | |
| KR101683302B1 (ko) | 박테리아 세포 내 로커스 증폭 방법 | |
| CN110004131A (zh) | 一种提高赖氨酸脱羧酶活性和稳定性的分子改造方法 | |
| CN101717787A (zh) | 肝组织特异性表达rtTA的载体及其应用 | |
| CN102241763A (zh) | 一种鱼类持续激活生长激素受体基因及制备方法和用途 | |
| CN114438083A (zh) | 识别猪PERV基因的sgRNA及其编码DNA和应用 | |
| CN110747216A (zh) | 一种多基因共表达成套载体及其应用 | |
| US20100304461A1 (en) | Portable, Temperature and Chemically Inducible Expression Vector for High Cell Density Expression of Heterologous Genes in Escherichia Coli | |
| CN113373163B (zh) | 一种密码子优化的沙眼衣原体ctl0286基因及其应用 | |
| CN110157721A (zh) | 一种痘苗病毒天坛株的示踪打靶质粒及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20191218 Patent event code: PA01071R01D Filing date: 20190809 Application number text: 1020190097531 |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200227 |
|
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200327 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200330 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20230322 Start annual number: 4 End annual number: 4 |